Chief Business Officer and Executive Vice President · Ultragenyx Pharmaceutical Inc. (RARE)

Thomas Kassberg

A named executive officer of Ultragenyx Pharmaceutical in every fiscal year CompBrief holds from FY2017 to FY2019. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2019

$2,456,501

Salary $474,000Stock awards $878,150

FY2018: $1,692,660

5th of 6 named executive officers at Ultragenyx Pharmaceutical by FY2019 total.

6 named officers on file for Ultragenyx Pharmaceutical, FY2019

Thomas Kassberg’s pay file — $29

  • 3 fiscal years of pay, line by line
  • 3 equity grants, each cited to its filing
  • RARE’s disclosed peer group of 19 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Ultragenyx Pharmaceutical’s whole pay program stands against its peers

  • Ultragenyx Pharmaceutical’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on RARE→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 29, 2020 (DEF 14A).

Free

Get Thomas Kassberg’s full pay file as a PDF — free

More than this page: up to 10 years of Thomas’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Thomas Kassberg compensation by year

Ultragenyx Pharmaceutical Summary Compensation Table · all 3 fiscal years held
In US dollars, as Ultragenyx Pharmaceutical reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2017FY2018FY2019
Salary$418,443$441,340$474,000
Bonus$0$0$0
Stock awards$335,243$242,150$878,150
Option awards$1,376,678$786,718$863,513
Non-equity incentive$168,600$189,600$206,901
Pension and deferred compensation$0$0$0
All other$32,697$32,852$33,937
Total$2,331,661$1,692,660$2,456,501

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Ultragenyx Pharmaceutical Inc. DEF 14A filed April 29, 2020, accession 0001193125-20-126182, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Ultragenyx Pharmaceutical Inc. filed document, accession 0001193125-20-126182. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2020.

$2.3M
$1.7M
$2.5M
FY17
FY18
FY19
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2019 year-end
TypeUnvested unitsValue at year-endExercise price
RSU7,000$298,897—
PSU6,000$256,260—
RSU4,500$192,195—
RSU3,584$153,073—
RSU1,500$64,065—
RSU1,000$42,710—
Option16,875—$48.43
Option7,812—$88.80
Option3,000—$70.57
Option21,500—$67.55

Per the Outstanding Equity Awards at Fiscal Year-End table in Ultragenyx Pharmaceutical Inc.'s FY2019 proxy; value at the fiscal year-end close, as the company printed it.

Ultragenyx Pharmaceutical’s named executive officers, FY2019

as the company reported each
Named executive officerRoleFY2019 total
Emil KakkisPresident and Chief Executive Officer$6,586,479
John PinionChief Quality Officer and Executive Vice President, Translational Sciences$3,370,530
Shalini SharpExecutive Vice President and Chief Financial Officer$2,605,521
Camille BedrosianChief Medical Officer and Executive Vice President$2,496,816
Thomas Kassberg · this pageChief Business Officer and Executive Vice President$2,456,501
Erik HarrisChief Commercial Officer and Executive Vice President$2,273,392

The full Ultragenyx Pharmaceutical compensation record

free company brief

This page is one person within Ultragenyx Pharmaceutical's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Ultragenyx Pharmaceutical proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Ultragenyx Pharmaceutical's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Thomas Kassberg's compensation dossier · One-time report. No refunds.